Literature DB >> 26152845

A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis.

Joanne Boldison1, Tarnjit K Khera2, David A Copland2, Madeleine L Stimpson2, Gemma L Crawford2, Andrew D Dick1,2, Lindsay B Nicholson1,2.   

Abstract

Experimental autoimmune uveoretinitis (EAU) in the C57BL/6J mouse is a model of non-infectious posterior segment intraocular inflammation that parallels clinical features of the human disease. The purpose of this study was to analyse the immune response to the four murine subunits of retinol binding protein-3 (RBP-3) to identify pathogenic epitopes to investigate the presence of intramolecular epitope spreading during the persistent inflammation phase observed in this model of EAU. Recombinant murine subunits of the RBP-3 protein were purified and used to immunize C57BL/6J mice to induce EAU. An overlapping peptide library was used to screen RBP-3 subunit 3 for immunogenicity and pathogenicity. Disease phenotype and characterization of pathogenic subunits and peptides was undertaken by topical endoscopic fundal imaging, immunohistochemistry, proliferation assays and flow cytometry. RBP-3 subunits 1, 2 and 3 induced EAU in the C57BL/6J mice, with subunit 3 eliciting the most destructive clinical disease. Within subunit 3 we identified a novel uveitogenic epitope, 629-643. The disease induced by this peptide was comparable to that produced by the uveitogenic 1-20 peptide. Following immunization, peptide-specific responses by CD4(+) and CD8(+) T-cell subsets were detected, and cells from both populations were present in the retinal inflammatory infiltrate. Intramolecular epitope spreading between 629-643 and 1-20 was detected in mice with clinical signs of disease. The 629-643 RBP-3 peptide is a major uveitogenic peptide for the induction of EAU in C57BL/6J mice and the persistent clinical disease induced with one peptide leads to epitope spreading.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmunity; chronic inflammation; epitope spreading; retina; uveitis

Mesh:

Substances:

Year:  2015        PMID: 26152845      PMCID: PMC4582971          DOI: 10.1111/imm.12503

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.

Authors:  Carly J Guyver; David A Copland; Claudia J Calder; Alessandro Sette; John Sidney; Andrew D Dick; Lindsay B Nicholson
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

2.  Thymic expression of autoantigens correlates with resistance to autoimmune disease.

Authors:  C E Egwuagu; P Charukamnoetkanok; I Gery
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

3.  T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.

Authors:  R T Carson; K M Vignali; D L Woodland; D A Vignali
Journal:  Immunity       Date:  1997-09       Impact factor: 31.745

4.  Sequence analysis of the mouse IRBP gene and cDNA.

Authors:  R Keith Shuler; Eleanore Gross; Wei-Ya He; Gregory I Liou; John M Nickerson
Journal:  Curr Eye Res       Date:  2002-05       Impact factor: 2.424

5.  Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2.

Authors:  Kenichi Namba; Nobuyoshi Kitaichi; Tomomi Nishida; Andrew W Taylor
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

6.  Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes.

Authors:  R R Caspi; B G Grubbs; C C Chan; G J Chader; B Wiggert
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

7.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.

Authors:  P V Lehmann; T Forsthuber; A Miller; E E Sercarz
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

8.  T-lymphocyte subsets in experimental autoimmune uveitis.

Authors:  C C Chan; M Mochizuki; R B Nussenblatt; A G Palestine; C McAllister; I Gery; D BenEzra
Journal:  Clin Immunol Immunopathol       Date:  1985-04

9.  A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease.

Authors:  M Yu; J M Johnson; V K Tuohy
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

10.  An immunologically privileged retinal antigen elicits tolerance: major role for central selection mechanisms.

Authors:  Dody Avichezer; Rafael S Grajewski; Chi-Chao Chan; Mary J Mattapallil; Phyllis B Silver; James A Raber; Gregory I Liou; Barbara Wiggert; Giavonni M Lewis; Larry A Donoso; Rachel R Caspi
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  5 in total

1.  Features of ectopic lymphoid-like structures in human uveitis.

Authors:  Simon J Epps; Natalie Coplin; Philip J Luthert; Andrew D Dick; Sarah E Coupland; Lindsay B Nicholson
Journal:  Exp Eye Res       Date:  2019-12-23       Impact factor: 3.467

2.  Combined Deficiency of the Melanocortin 5 Receptor and Adenosine 2A Receptor Unexpectedly Provides Resistance to Autoimmune Disease in a CD8+ T Cell-Dependent Manner.

Authors:  Trisha McDonald; Fauziyya Muhammad; Kayleigh Peters; Darren J Lee
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

3.  Stochastic Effects in Autoimmune Dynamics.

Authors:  Farzad Fatehi; Sergey N Kyrychko; Aleksandra Ross; Yuliya N Kyrychko; Konstantin B Blyuss
Journal:  Front Physiol       Date:  2018-02-02       Impact factor: 4.566

Review 4.  Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopathies?

Authors:  Grazyna Adamus
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

Review 5.  Molecular Mimicry and Uveitis.

Authors:  Gerhild Wildner; Maria Diedrichs-Möhring
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.